Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies

Trial Profile

A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BP 1002 (Primary)
  • Indications Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Bio-Path Holdings
  • Most Recent Events

    • 21 Nov 2019 According to a Bio-Path Holdings media release, the trial is expected to be conducted at several leading cancer centers, including The University of Texas MD Anderson Cancer Center and the Georgia Cancer Center. William G. Wierda will serve as Principal Investigator for the trial.
    • 21 Nov 2019 According to a Bio-Path Holdings media release, the U.S. Food and Drug Administration (FDA) has reviewed by the FDA's Office of Oncologic Diseases, Division of Hematologic Malignancies and cleared the Investigational New Drug (IND) application.
    • 19 Nov 2019 Planned initiation date changed from 1 Nov 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top